Feasibility of oncoplastic surgery in breast cancer patients with associated in situ carcinoma.

Q2 Medicine

Journal of Buon Pub Date : 2021-09-01

Alexandra Caziuc, David Andras, Vlad Fagarasan, George Calin Dindelegan

{"title":"Feasibility of oncoplastic surgery in breast cancer patients with associated in situ carcinoma.","authors":"Alexandra Caziuc, David Andras, Vlad Fagarasan, George Calin Dindelegan","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: Wide surgical margins are needed in order to treat locally the in situ ductal carcinoma of the breast. Breast conserving surgery using oncoplastic techniques in treating in situ ductal carcinoma can be a good option improving cosmetic and pathological outcome.Methods: Between January 2019 and July 2019, 76 patients with invasive carcinoma associated with in situ ductal carcinoma were eligible for breast conserving surgery and were admitted to Cluj-Napoca First Surgical Clinic. Patients were divided into two groups, one group with simple lumpectomy and the other group with oncoplastic procedure.Results: 26 patients had oncoplastic surgery while 47 patients underwent simple lumpectomy. Lateral mammoplasty was the most frequent oncoplastic procedure (41.3%). Mean tumor size was 3.19 cm (SD 0.76) in the oncoplastic cohort while in the simple lumpectomy cohort the mean tumor size was 1.20 cm (SD 0.89). Regarding tumor size, better surgical resection margins were obtained using oncoplastic procedure (p=0.051). No difference between groups in terms of perioperative complications was observed (p=0.32).Conclusions: Breast conserving surgery with oncoplastic techniques are oncologically safe, obtaining better surgical margins in ductal carcinoma in situ.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"1970-1974"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Wide surgical margins are needed in order to treat locally the in situ ductal carcinoma of the breast. Breast conserving surgery using oncoplastic techniques in treating in situ ductal carcinoma can be a good option improving cosmetic and pathological outcome.

Methods: Between January 2019 and July 2019, 76 patients with invasive carcinoma associated with in situ ductal carcinoma were eligible for breast conserving surgery and were admitted to Cluj-Napoca First Surgical Clinic. Patients were divided into two groups, one group with simple lumpectomy and the other group with oncoplastic procedure.

Results: 26 patients had oncoplastic surgery while 47 patients underwent simple lumpectomy. Lateral mammoplasty was the most frequent oncoplastic procedure (41.3%). Mean tumor size was 3.19 cm (SD 0.76) in the oncoplastic cohort while in the simple lumpectomy cohort the mean tumor size was 1.20 cm (SD 0.89). Regarding tumor size, better surgical resection margins were obtained using oncoplastic procedure (p=0.051). No difference between groups in terms of perioperative complications was observed (p=0.32).

Conclusions: Breast conserving surgery with oncoplastic techniques are oncologically safe, obtaining better surgical margins in ductal carcinoma in situ.

本刊更多论文

乳腺癌合并原位癌患者肿瘤整形手术的可行性。

目的:扩大手术切缘是治疗乳腺原位导管癌的必要条件。保乳手术采用肿瘤整形技术治疗原位导管癌是改善美容和病理结果的一个很好的选择。方法:2019年1月至2019年7月，克卢日-纳波卡第一外科诊所收治76例符合保乳手术条件的浸润性癌合并原位导管癌患者。患者分为两组，一组采用单纯的乳房肿瘤切除术，另一组采用肿瘤成形术。结果:26例行肿瘤整形手术，47例行单纯乳房肿瘤切除术。侧乳成形术是最常见的肿瘤整形手术(41.3%)。肿瘤肿瘤组平均肿瘤大小为3.19 cm (SD 0.76)，单纯乳房肿瘤切除术组平均肿瘤大小为1.20 cm (SD 0.89)。在肿瘤大小方面，肿瘤成形术获得了更好的手术切除边缘(p=0.051)。两组围手术期并发症无统计学差异(p=0.32)。结论:保乳手术与肿瘤整形技术在肿瘤上是安全的，在导管原位癌中获得更好的手术切缘。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.